Table 2 Characteristics associated with MSM achieving viral suppression in the first year of treatment
Characteristic | Viral Suppression , n (%) | ||
|---|---|---|---|
No (n = 410) | Yes (n = 2448) | P-value | |
Province | |||
 British Columbia | 140 (34) | 714 (29) | 0.011 |
 Ontario | 158 (39) | 887 (36) | |
 Quebec | 112 (27) | 847 (35) | |
Age (years) | 38 (33–44) | 40 (34–46) | 0.002 |
Ethnicity | |||
 Caucasian | 216 (53) | 1104 (45) | 0.002 |
 Black | 8 (2) | 43 (2) | |
 Aboriginal | 17 (4) | 53 (2) | |
 Other | 40 (10) | 331 (14) | |
 Unknown | 129 (31) | 917 (37) | |
History of IDU | |||
 No | 336 (82) | 2219 (91) | <0.001 |
 Yes | 60 (15) | 187 (8) | |
 Unknown | 14 (3) | 42 (2) | |
Hepatitis C status | |||
 No | 321 (78) | 2092 (85) | 0.001 |
 Yes | 68 (17) | 263 (11) | |
 Unknown | 21 (5) | 93 (4) | |
Era of cART initiation | |||
 2000–2003 | 152 (37) | 577 (24) | <0.001 |
 2004–2007 | 127 (31) | 804 (33) | |
 2008–2012 | 131 (32) | 1067 (44) | |
Number of viral load tests per year | |||
 Less than 3 | 115 (28) | 468 (19) | <0.001 |
 3–4 | 188 (46) | 1402 (57) | |
 5–6 | 48 (12) | 312 (13) | |
 More than 6 | 59 (14) | 266 (11) | |
Initial 3rd ARV class | |||
 NNRTI | 140 (34) | 1137 (46) | <0.001 |
 Unboosted PI | 39 (10) | 89 (4) | |
 Boosted PI | 194 (47) | 1045 (43) | |
 Other | 37 (9) | 177 (7) | |
Initial 3rd ARV | |||
 Nevirapine | 41 (10) | 211 (9) | <0.001 |
 Efavirenz | 105 (26) | 928 (38) | |
 Lopinavir | 73 (18) | 351 (14) | |
 Atazanavir | 79 (19) | 499 (20) | |
 Other | 112 (27) | 459 (19) | |
NRTI combination | |||
 Tenofovir/emtricitabine | 134 (33) | 1083 (44) | <0.001 |
 Zidovudine/lamivudine | 114 (28) | 480 (20) | |
 Tenofovir/lamivudine | 27 (7) | 180 (7) | |
 Abacavir/lamivudine | 58 (14) | 410 (17) | |
 Stavudine/lamivudine | 43 (10) | 169 (7) | |
 Other | 34 (8) | 126 (5) | |
AIDS-defining illness | |||
 No | 307 (75) | 1977 (81) | 0.006 |
 Yes | 88 (21) | 371 (15) | |
 Unknown | 15 (4) | 100 (4) | |
Viral load (log10 copies/mL) | 5.00 (4.75–5.00) | 4.93 (4.48–5.00) | <0.001 |
CD4 count (cells/uL) | 190 (100–310) | 231 (134–327) | 0.001 |